Rice Hall James & Associates’s Pediatrix Medical MD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
Sell
-22,994
Closed -$1.59M 301
2017
Q1
$1.59M Sell
22,994
-331
-1% -$23K 0.08% 219
2016
Q4
$1.55M Sell
23,325
-3,772
-14% -$245K 0.08% 221
2016
Q3
$1.79M Sell
27,097
-1,063
-4% -$72.7K 0.09% 202
2016
Q2
$2.04M Buy
28,160
+833
+3% +$57.3K 0.12% 170
2016
Q1
$1.77M Sell
27,327
-312
-1% -$20.7K 0.1% 193
2015
Q4
$1.98M Sell
27,639
-15,412
-36% -$1.14M 0.11% 174
2015
Q3
$3.31M Sell
43,051
-1,621
-4% -$131K 0.21% 105
2015
Q2
$3.31M Sell
44,672
-3,494
-7% -$251K 0.19% 121
2015
Q1
$3.49M Buy
48,166
+1,110
+2% +$77.2K 0.2% 125
2014
Q4
$3.11M Sell
47,056
-495
-1% -$30.2K 0.19% 138
2014
Q3
$2.61M Sell
47,551
-9,804
-17% -$556K 0.18% 153
2014
Q2
$3.33M Sell
57,355
-15,450
-21% -$909K 0.22% 97
2014
Q1
$4.51M Sell
72,805
-1,207
-2% -$70.2K 0.33% 66
2013
Q4
$3.95M Sell
74,012
-6,202
-8% -$333K 0.29% 77
2013
Q3
$4.03M Sell
80,214
-3,748
-4% -$183K 0.39% 67
2013
Q2
$3.85M Buy
+83,962
New +$3.76M 0.38% 63

Other funds holding MD

Rice Hall James & Associates's MD Position: Q2 2017 in Review

Rice Hall James & Associates sold out of Pediatrix Medical (MD) in Q2 2017, closing a stake of 22,994 shares — an estimated $1.59M sold.

Rice Hall James & Associates first reported a position in MD in Q2 2013 and held it in 16 quarters. The position peaked at $4.51M in Q1 2014. 332 funds tracked by Wall St. Rank hold MD as of Q2 2017.

  • Rice Hall James & Associates reported no remaining Pediatrix Medical position as of Q2 2017 after selling out during the quarter.
  • Rice Hall James & Associates sold 22,994 Pediatrix Medical shares in Q2 2017, an estimated $1.59M.
  • Rice Hall James & Associates first reported a position in Pediatrix Medical in Q2 2013 and held it in 16 quarters.
  • Rice Hall James & Associates's Pediatrix Medical position peaked at $4.51M in Q1 2014.
  • 332 funds tracked by Wall St. Rank held Pediatrix Medical as of Q2 2017.

Based on Rice Hall James & Associates's 13F filing for Q2 2017, filed 2 Aug 2017.